Unexplained (non-cardiac) chest pain

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 6, Issue 5, 2006, Pages 445-449

  Fox, Mark ^a   Forgacs, Ian ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Ambulatory pH monitoring; Chest pain; Gastro oesophageal reflux disease; Oesophageal motility disorders; Proton pump inhibitor; Visceral hypersensitivity

Indexed keywords

AMITRIPTYLINE; GLYCERYL TRINITRATE; HISTAMINE H2 RECEPTOR ANTAGONIST; NIFEDIPINE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; SEROTONIN UPTAKE INHIBITOR; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT;

ABSENCE OF SIDE EFFECTS; AMBULATORY MONITORING; BEHAVIOR THERAPY; CLINICAL ASSESSMENT; CLINICAL TRIAL; COGNITIVE THERAPY; DOSE RESPONSE; EVALUATION; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HUMAN; MANOMETRY; REVIEW; TACHYPHYLAXIS; THORAX PAIN; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 33750624607     PISSN: 14702118     EISSN: None     Source Type: Journal    
DOI: 10.7861/clinmedicine.6-5-445     Document Type: Review

References (16)

1. Eslick GD, Coulshed DS, Talley NJ. Review article: the burden of illness of non-cardiac chest pain. Aliment Pharmacol Ther 2002;16:1217-23.
2. Chambers J, Bass C. Chest pain with normal coronary anatomy: a review of natural history and possible etiologic factors. Review. Prog Cardiovasc Dis 1990;33:161-84.
3. Liuzzo JP, Ambrose JA, Diggs P. Proton-pump inhibitor use by coronary artery disease patients is associated with fewer chest pain episodes, emergency department visits and hospitalizations. Aliment Pharmacol Ther 2005;22:95-100.
4. Drossman DA, Whitehead WE, Toner BB et al. What determines severity among patients with painful functional bowel disorders? Am J Gastroenterol 2000;95:974-80.
5. National Institute of Clinical Excellence. Dyspepsia: management of dyspepsia in adults in primary care. Newcastle upon Tyne: NICE, 2004.
6. Kapoor N, Bassi A, Sturgess R, Bodger K. Predictive value of alarm features in a rapid access upper gastrointestinal cancer service. Gut 2005;54:40-5.
7. Wang WH, Huang JQ, Zheng GF et al. Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with noncardiac chest pain?: a meta-analysis. Review. Arch Intern Med 2005;165:1222-8.
8. Dickman R, Emmons S, Cui H et al. The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial. Aliment Pharmacol Ther 2005;22:547-55.
9. Bredenoord AJ, Weusten BL, Curvers WL, Timmer R, Smout AJ. Determinants of perception of heartburn and regurgitation. Review. Gut 2006;55:313-8.
10. Tutuian R, Castell DO. Esophageal function testing: role of combined multichannel intraluminal impedance and manometry. Gastrointest Endosc Clin N Am 2005;15:265-75.
11. Dekel R, Pearson T, Wendel C et al. Assessment of oesophageal motor function in patients with dysphagia or chest pain - the Clinical Outcomes Research Initiative experience. Aliment Pharmacol Ther 2003;18:1083-9.
12. Hobson AR, Furlong PL, Sarkar S et al. Neurophysiologic assessment of esophageal sensory processing in noncardiac chest pain. Gastroenterology 2006;130:80-8.
13. Ofman JJ, Gralnek IM, Udani J, Fennerty MB, Fass R. The cost-effectiveness of the omeprazole test in patients with noncardiac chest pain. Am J Med 1999;107:219-27.
14. Cremonini F, Wise J, Moayyedi P, Talley NJ. Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a metaanalysis. Am J Gastroenterol 2005;100:1226-32.
15. Cannon RO 3rd, Quyyumi AA, Mincemoyer R et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med 1994;330:1411-7.
16. Drossman DA, Toner BB, Whitehead WE et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterohgy 2003;125:19-31.